• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23734 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     The Danish Health Technology Council (DHTC) [Assessment of endovascular aortic repair (EVAR)]
2025     Swiss Federal Office of Public Health (FOPH) Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus
2025     Norwegian Medical Products Agency (NOMA) Continuous and flash glucose monitoring in patients with type 2 diabetes treated with insulin
2025     Norwegian Medical Products Agency (NOMA) [Photon-counting detector computed tomography]
2025     Norwegian Medical Products Agency (NOMA) [Volatile gas capture technology. Summary of a health technology assessment by Scottish Health Technologies Group: health technology assessment without submitted documentation]
2025     Norwegian Medical Products Agency (NOMA) [Tumor-treating fields (Optune) for treatment of glioblastoma: a rapid health technology assessment with submitted documentation]
2025     Norwegian Medical Products Agency (NOMA) [Magnetic resonance guided high-intensity focused ultrasound for treatment of essential tremor: single technology assessment]
2025     Norwegian Medical Products Agency (NOMA) [A leadless pacemaker, MicraTM Transcatheter Pacing System, in (sub-groups of) patients with indication for single-chamber ventricular pacing: a single technology re-assessment]
2025     Health Information and Quality Authority (HIQA) Health technology assessment (HTA) of teledermatology for triage of primary care referrals
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the tiered system of emergency structures in hospitals]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for prostate cancer]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI / SSNRI: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tricyclic antidepressants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Agility training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anticonvulsants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Strength training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endurance training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy for insomnia: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mindfulness-based stress reduction: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on lung cancer screening using low-dose computed tomography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on smoking cessation options]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for implantation of unicondylar sled prosthesis - Update of Project V21-02]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in knee replacement revision surgery - Update of Project V21-03]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for total knee replacement – Update of Project V21-01]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific evaluation of the relationship between volume of services and quality of treatment outcome for rare diseases]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of cardiac magnetic resonance imaging in coronary heart disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2025     Norwegian Medical Products Agency (NOMA) Intravenous ketamine for treatment-resistant depression
2025     Belgian Health Care Knowledge Centre (KCE) Economic evaluation of whole genome sequencing for children with developmental disorders (Study 2024-09)
2025     Belgian Health Care Knowledge Centre (KCE) Update of prostate cancer screening recommendations (Study 2024-10)
2025     Belgian Health Care Knowledge Centre (KCE) Update of breast cancer screening recommendations (Study 2024-11)
2025     Belgian Health Care Knowledge Centre (KCE) Evaluation of novel blood-based brain biomarkers for mild traumatic brain injuries (Study 2023-11)
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of graft damage in kidney and heart recipient patients using donor-derived free DNA (dd-cfDNA)]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Branched endovascular prostheses for the treatment of aortic arch pathology]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of care models based on the incorporation of psychologists in primary care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline (CPG) update palliative care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline on deprescribing antidepressants]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) Monitoring study protocol: left ventricular assist devices destination therapy
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for aortic aneurysm interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of colorectal cancer in people with a family risk]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Rheumatoid Arthritis“]
2025     Swiss Federal Office of Public Health (FOPH) Multigene-expression tests for breast cancer
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2024     Austrian Institute for Health Technology Assessment (AIHTA) Telehealth in diabetes – EU mapping and systematic evaluation of organisational aspects
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in dystonia, dyspareunia, and strabismus]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Threshold values in health economic evaluations and decision-making
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Artificial Intelligence in health care with a focus on hospitals: methodological considerations for health technology assessment: a scoping review
2024     Austrian Institute for Health Technology Assessment (AIHTA) Oncological breast cancer care in selected European countries: cross-sectoral cancer care models
2024     Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets]
2024     Gesundheit Osterreich GmbH (GOeG) [Long-term effectiveness of early interventions for children and adolescents with psychological stress]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure]
2024     Scottish Health Technologies Group (SHTG) Digital fracture liaison service
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Rigid-platform (TEM/ TEO) or flexible-platform (TAMIS) endoscopic transanal surgery for the treatment of rectal lesions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – 2nd Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polihexanide (Acanthamoeba keratitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (mucormycosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (aspergillosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Lorviqua (ALK+ NSCLC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Velexbru (primary CNS b-cell lymphoma)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Padcev (urothelial cancer)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Nubeqa (Prostate Cancer - mCSPC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Crysvita (XLH - x-linked hypophosphatemia)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Altuviiio lyophilized powder solution for IV injection]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (renal cell carcinoma - RCC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (malignant pleural mesothelioma - MPM)]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (ESCC - first-line treatment)
2024     Center for Drug Evaluation (CDE) [HTA for Medical Device: Metallic biliary stents (Rapid HTA report)]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous treatment for moderate to severe mitral valve insufficiency]
2024     Institute for Clinical and Economic Review (ICER) Assessment of barriers to fair access
2024     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2023
2024     Institute for Clinical and Economic Review (ICER) Managing the challenges of paying for gene therapy: strategies for market action and policy reform
2024     Institute for Clinical and Economic Review (ICER) Tabelecleucel for epstein-barr virus positive post-transplant lymphoproliferative disease: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
2024     Institute for Clinical and Economic Review (ICER) Imetelstat for anemia in myelodysplastic syndrome: effectiveness and value